Neuphoria Therapeutics Inc.
General ticker "NEUP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $22.2M (TTM average)
Neuphoria Therapeutics Inc. does not follow the US Stock Market performance with the rate: -8.0%.
Estimated limits based on current volatility of 2.5%: low 2.72$, high 2.86$
Factors to consider:
- Total employees count: 24 as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Operating losses, Manufacturing issues, Labor/talent shortage/retention
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-06-30 to 2028-06-29
- 2026-06-30 to 2027-06-30 estimated range: [2.52$, 5.96$]
- 2027-06-30 to 2028-06-29 estimated range: [1.99$, 4.85$]
Financial Metrics affecting the NEUP estimates:
- Negative: with PPE of -0.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: -1.37 < Return on assets ratio (scaled to [-100,100]) of -0.05
- Positive: -0.07 < Investing cash flow per share per price, % of 0
- Negative: Shareholder equity ratio, % of 85.69 > 81.82
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NEUP quotes
Long-term NEUP plot with estimates
Financial data
| YTD | 2024-06-30 | 2025-06-30 | 2026-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $15.65MM | $1.17MM |
| Operating Expenses | $17.89MM | $16.78MM | $10.98MM |
| Operating Income | $-17.89MM | $-1.13MM | $-9.81MM |
| Non-Operating Income | $2.31MM | $0.29MM | $-3.78MM |
| R&D Expense | $9.42MM | $9.01MM | $3,545.42MM |
| Income(Loss) | $-15.58MM | $-0.84MM | $-13.59MM |
| Taxes | $-0.09MM | $-0.47MM | $-0.14MM |
| Net Income(Loss)* | $-15.49MM | $-0.37MM | $13,425.03MM |
| Stockholders Equity | $17.49MM | $19.00MM | $24,600.02MM |
| Assets | $27.65MM | $28.59MM | $28,709.02MM |
| Operating Cash Flow | $-14.68MM | $0.08MM | $-12,353.07MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $15.11MM | $1.53MM | $17,915.88MM |
| Earnings Per Share** | $-0.10 | $-0.23 | $3,053.92 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.